Leukemia Clinical Trials in Florida

Showing 121-140 of 470 trials

TERMINATEDPHASE149 miles

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

NCT03760523

This study is to determine the safety and recommended dosing of Minnelide in Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

H. Lee Moffitt Cancer Center and Research Institute27 participantsStarted Apr 2019

Tampa, Florida, United States

TERMINATEDPHASE249 miles

TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

NCT04163718

The purpose of this study is to see how safe and effective the investigational drug umbralisib (TGR-1202) is in individuals with Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

H. Lee Moffitt Cancer Center and Research Institute12 participantsStarted Nov 2019

Tampa, Florida, United States

ACTIVE_NOT_RECRUITINGPHASE249 miles

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992

This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET AmplificationLung Adenocarcinoma Stage IIIB/IV

EMD Serono Research & Development Institute, Inc.337 participantsStarted Sep 2016

Duarte, California, United States • Encinitas, California, United States • Orange, California, United States +173 more locations

PreviousPage 7 of 24Next

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Leukemia Trials in Other Cities

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Quality of Life Model for Older Patients With AML

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Other Conditions in Florida